Shares are trading at $1.69 quite a bit lower than $1.88, the 50 day moving average and significantly below the 200 day moving average of $3.08. The 50 day moving average was down by -10.240% and the 200 day average was down $-1.39. 167K shares changed hands in the last trading session. Overall, volume was down 68.29% under the stocks normal daily volume.
Investors are a little more bearish on shares of the company lately at least if you consider the change in short interest. The company realized a rise in short interest of 55.27% between September 29, 2017 and October 13, 2017. Short shares grew 252,941 over that timeframe. With short interest at 710,627 and short average daily volume at 651,821, days to cover is 1.0 and the percentage of shorted shares is 0.16% as of October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (CYCC). As of quarter end Citadel Advisors LLC had disposed of a total of 7,482 shares trimming its position 16.4%. The value of the company’s investment in Cyclacel Pharmaceuticals, Inc. went from $23,000 to $15,000 decreasing 34.8% for the reporting period. As of the end of the quarter Raymond James Financial Services Advisors, Inc. had bought 10,000 shares growing its holdings by 98.8%. The value of the investment in Cyclacel Pharmaceuticals, Inc. decreased from $38,000 to $37,000 a change of 2.6% quarter over quarter.
Cyclacel Pharmaceuticals, Inc., launched on January 5, 1996, operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. The Business’s family of anticancer drugs acts on the cell cycle..